Key facts
- Tcn Prime’s last known valuation is $2.7M (Jun 2024).
- It has raised $2.5M; the latest was Accelerator/Incubator in Mar 2026.
- Notable investors include Osaka University Venture Capital, 0>1 Start, Kansai Startup Incubation, Kobe University Capital, Neuroceuticals — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tcn Prime
- ·The full record, as it builds
Funding rounds
No funding rounds for Tcn Prime are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tcn Prime
Manufacturer of medical devices intended for the cardiovascular medicine field. The company offers medical devices that are distinct from extracorporeal circulation with artificial lung and pump catheters, with a balloon catheter for the treatment of aortic valve stenosis, enabling the healthcare industry to save the lives of patients by placing minimal strain on the patient's body
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2023
- Website
- tcn-prime.jp/
- Ownership
- Privately Held (backing)
Tcn Prime doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tcn Prime shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tcn Prime in its N-PORT filings yet. We sweep new filings monthly.